p53 and the ribosomal protein L5 participate in high molecular mass complex formation with protein kinase CK2 in murine teratocarcinoma cell line F9 after serum stimulation and cisplatin treatment.
Using the murine teratocarcinoma cell line F9 we investigated the influence of serum stimulation and cisplatin treatment on the p53, CK2, MDM2 levels. Both treatments led to an increase of p53, though with different kinetics; the other proteins investigated were not affected. We present direct evidence by immunoprecipitation for an association of protein kinase CK2 holoenzyme (alpha2beta2), p53, and the ribosomal protein L5. The results suggest complexes between the CK2 holoenzyme and p53 but also p53/CKbeta complexes. Furthermore we provide evidence for the existence of high molecular mass complexes of CK2 in vivo. This is the first evidence that, under physiological conditions, protein kinase CK2 does not exist solely as a heterotetramer, but predominantly in association with other proteins.
Guerra
B
B
Odense Universitet, Biokemisk Institut, Denmark.
Issinger
O G
OG
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001798:Blood Proteins / Q000494:pharmacology*; D047390:Casein Kinase II; D002945:Cisplatin / Q000494:pharmacology*; D051379:Mice; D011233:Precipitin Tests; D011485:Protein Binding; D017346:Protein Serine-Threonine Kinases / Q000737:chemistry / Q000378:metabolism*; D012269:Ribosomal Proteins / Q000378:metabolism*; D018243:Teratocarcinoma / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry / Q000378:metabolism*
D000970:Antineoplastic Agents; D001798:Blood Proteins; D012269:Ribosomal Proteins; D016159:Tumor Suppressor Protein p53; C029742:ribosomal protein L5; D047390:Casein Kinase II; D017346:Protein Serine-Threonine Kinases; D002945:Cisplatin